CervoMed Inc. CRVO 深 滬
等待開盤 06-25 09:30:00 美东时间
3.26
-0.460
-12.37%
華盛通- 最 高3.70
- 今 開3.58
- 成交量 188.34万股
- 最 低 3.04
- 昨 收 3.72
- 總市值 3018.34万
- 52周最高 13.13
- 市盈率 靜 --
- 換手率 20.34%
- 52周最低 2.13
- 委 比 -99.65%
- 總股本 925.87万
- 歷史最高 17437.50
- 量 比 0.03
- 振 幅 17.74%
- 歷史最低 1.80
- 每 手 1
- 風險率 2.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CervoMed Raises $10 Million in Direct Offering
CervoMed ( ($CRVO) ) just unveiled an update. On June 22, 2026, CervoMed Inc. c...
06-23 04:30
CervoMed Receives U.S. Patent For Its Neflamapimod Drug Candidate For The Treatment Of Dementia With Lewy Bodies
CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) related to a new patent protecti...
06-18 19:07
CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
CervoMed Inc. has received a patent allowance from the USPTO for its drug candidate, neflamapimod, targeting the treatment of pure dementia with Lewy bodies (DLB) without substantial Alzheimer’s disease-like tau pathology. The patent, valid until 2042, aims to protect the company's strategy for treating pure DLB, a condition with no approved therapies in the US or EU. CervoMed is advancing neflamapimod through clinical trials, with a Phase 3 tria...
06-18 11:00
美股夜盘 | Micropolis Holding Co.涨54.33%，金生游乐涨35.00%
CervoMed Inc.涨-14.16%；Nexentis Technologies Inc.涨-13.40%；Neumora Therapeutic涨-9.62%
06-17 08:05
美股夜盘 | SpaceX涨超4%，SpaceX称承销商已行使绿鞋期权，IPO总募资额增至857亿美元
SpaceX涨超4%，SpaceX称承销商已行使绿鞋期权，IPO总募资额增至857亿美元；CervoMed飙涨近40%，HIGH TIDE涨14.67%，爱奇艺涨2.86%>>
06-16 08:05
CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies
CervoMed Inc. has secured $10.5 million in a private placement to extend its cash runway into Q2 2027 and advance neflamapimod, a drug targeting dementia with Lewy bodies (DLB), into Phase 3 development. The funding will also support upcoming milestones, including 24-week data from a Phase 2a trial in nonfluent variant primary progressive aphasia (nfvPPA) and the initiation of a Phase 2a trial in amyotrophic lateral sclerosis (ALS). Key strategic...
06-10 11:30
CervoMed Q1 EPS $(0.86) Misses $(0.78) Estimate
CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.78) by 10.26 percent. This is a 53.57 percent decrease over losses of $(0.56) per share from the
05-16 07:02
美股大行评级 | 潜在涨幅15%！15家大行集体上调德州仪器目标价；CSX运输、拉姆研究、金沙集团、马斯可木业、Vertiv Holdings等获多家大行上调目标价
今日重点评级关注：花旗：维持Pegasystems"买入"评级，目标价从70美元升至71美元；巴克莱：维持曼哈顿联合软件"超配"评级，目标价从236美元升至239美元
04-24 12:10
CervoMed Presents Data On Neflamapimod That May Increase Size, Enhance Function Of Basal Forebrain In Participants With Dementia With Lewy Bodies
Today at the 2026 AAN Annual Meeting in Chicago, the first-ever, placebo-controlled magnetic resonance imaging (MRI) analyses providing evidence that neflamapimod may increase the size and enhance the function of the
04-22 19:34
